IDEXX Laboratories (NASDAQ:IDXX) Stock Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on May 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in IDEXX Laboratories stock on April 9th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/29/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of Dayforce (NYSE:DAY) on 4/28/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/24/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/10/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 4/9/2025.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $475.07 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88. The business’s 50 day moving average is $419.61 and its two-hundred day moving average is $428.18. The company has a market capitalization of $38.50 billion, a P/E ratio of 44.52, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.71 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.98% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on IDXX. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research note on Monday, April 14th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $524.75.

Institutional Investors Weigh In On IDEXX Laboratories

Institutional investors and hedge funds have recently made changes to their positions in the stock. Tidal Investments LLC lifted its stake in IDEXX Laboratories by 7.6% during the third quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock worth $3,188,000 after purchasing an additional 444 shares in the last quarter. Franklin Resources Inc. lifted its stake in IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after acquiring an additional 34,305 shares in the last quarter. American Trust acquired a new position in IDEXX Laboratories during the 3rd quarter worth about $757,000. Oddo BHF Asset Management Sas purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $1,128,000. Finally, GAMMA Investing LLC grew its position in IDEXX Laboratories by 3.3% in the 4th quarter. GAMMA Investing LLC now owns 1,533 shares of the company’s stock valued at $634,000 after acquiring an additional 49 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.